Congratulations to Lepu Biopharma Co., Ltd. (2157.HK) on its Successful Listing

Lepu Biopharma Co., Ltd. has been successfully listed on the Mainboard of HKSE on 23 February 2022. AVISTA Group is honored to be engaged in providing valuation services.

Incorporated in 2018, Lepu Biopharma is a biopharmaceutical company focusing on oncology therapeutics. Lepu Biopharma is the industry leader in ADC therapeutics in China, with an integrated end-to-end platform from drug discovery, clinical development, CMC to GMP compliant production. It has built a product pipeline with clinical efficacy and commercialization synergies. The pipeline features three major products: broad-spectrum anti-tumor drugs (primarily anti-PD1 antibody drugs), and ADC and oncolytic virus drug candidates.

Lepu Biopharma has a range of oncology products in its pipeline, including eight clinical-stage drug candidates, three pre-clinical drug candidates, and three clinical-stage combination therapies of the drug candidates. Among the eight clinical-stage drug candidates, five are in targeted therapy and three are in immunotherapy, with two of the three being immune checkpoint drugs and one being oncolytic virus drug. Lepu Biopharma has initiated 28 clinical trials, among which three had entered registration trial phase and two were ongoing in the U.S.

Lepu Biopharma houses the leading ADC drug candidate pipeline in China in terms of the number of clinical-stage ADC drug candidates, according to Frost & Sullivan. Its comprehensive ADC and oncolytic virus drug candidates pipeline creates synergies and maximizes its competitive strength in commercialization.